2015-10-16
294
| полный ответ (Complete Response - CR) | исчезновение всех основных очагов. Любой из увеличенных лимфатических узлов (основных или дополнительных) должен иметь короткую ось менее 10 мм; |
| частичный ответ (Partial Response - PR) | уменьшение суммы диаметров основных очагов не менее чем на 30%; |
| прогрессирование заболевания (Progressive Disease - PD) | увеличение на 20% и более суммы диаметров основных очагов, которая в абсолютном выражении составляет не менее 5 мм; появление одного или нескольких новых очагов; |
| стабилизация заболевания (Stable Disease - SD) | несоответствие критериям CR или PR при отсутствии PD. |
Оценка дополнительных (non-target lesions) очагов опухолевого поражения (роста).
| полный ответ (Complete Response - CR) | исчезновение всех дополнительных очагов и нормализация уровня опухолевых маркеров. Все лимфатические узлы должны иметь размер менее 10 мм по короткой оси; |
| Non-CR/Non-PD: | сохранение одного или нескольких основных очагов и/или сохранение уровня опухолевого маркера выше нормы; |
| прогрессирование заболевания (Progressive Disease - PD) | однозначная прогрессия дополнительных очагов, появление одного или нескольких новых очагов. |
| Критерии адекватности операции | |
| R0 | полная резекция с отсутствием признаков опухолевого роста при гистопатологическом исследовании |
| R1 | признаки опухолевого роста в краях удаленной ткани при гистологическом исследовании |
| R2 | остатки опухоли, макроскопически видимые во время операции |
Литература
|
|
|
1. A. Berruti, E. Baudin, H. Gelderblom, H. R. Haak, F. Porpiglia, M. Fassnacht, G. Pentheroudakis - Adrenal cancer: ESMO (European Society for Medical Oncology) Clinical Practice Guidelines for diagnosis, treatment and follow-up on behalf of the ESMO Guidelines Working Group. - Annals of Oncology 2012 vol. 23 — p131–138
2. NCCN Clinical Practice Guidelines in Oncology, Neuroendocrine tumor, Version 1.2014
3. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 2005; 12:667.
4. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, Roher HD Adrenal involvement in multiple endocrine neoplasia type 1. - 2002 - World J Surg 26:891-896.
5. Gicquel C, Le Bouc Y Molecular markers for malignancy in adrenocortical tumors.- 1997 - Horm Res 47:269-272.
6. Бельцевич Д. Г., Кузнецов Н. С., Солдатова Т. В., Ванушко В. Э. Инциденталома надпочечников // Эндокринная хирургия. 2009. №1.
7. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest 2006;29:298-302.
8. Young W.F.,Jr. The Incidentally Discovered Adrenal Mass. N Engl J Med 2007; 356:601-10.
9. Cawood T J, Hunt P J, O’Shea D, Cole D and Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Literature review. European Journal of Endocrinology – 2009. -Vol 161 513–527.
10. Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi B Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002 - 147:489–494. Terzolo M, Reimondo G, Bovio S, Angeli A Subclinical Cushing’s syndrome. Pituitary 2004 - 7:217–223
11. Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, Trésallet C, Amar L, Rault A, Henry JF, Carnaille B. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012 Jun;36(6):1382-8.
|
|
|
12. Li XG, Zhang DX, Li X, Cui XG, Xu DF, Li Y, Gao Y, Yin L, Ren JZ Adrenocorticotropic hormone-producing pheochromocytoma: a case report and review of the literature. - Chin Med J (Engl). 2012 Mar;125(6):1193-6.
13. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E, Caron P. Ectopic Cushing's syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. - Gynecol Endocrinol. 2009 Sep;25(9):624-7.
14. Gardet V et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 2001-19: 1029–1035.
15. L.K. Nieman, B.M.K. Biller, J. W. Findling, J.Newell-Price, M.O. Savage, P.M. Stewart, and V.M. Montori. The diagnosis of Cushing’s syndrome:an endocrine society clinical practice guideline Journal of Clin Endoc & Met, 2008, 93(5): 1526–1540.
16. Newell-Price J, Trainer P, Besser M, Grossman A 1998 The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing's states. Endocr Rev 19:647–672
17. Pecori Giraldi F, Ambrogio AG, De Martin M, Fatti LM, Scacchi M, Cavagnini F 2007 Specificity of first-line tests for the diagnosis of Cushing’s syndrome: assessment in a large series. J Clin Endocrinol Metab 92:4123–4129.
18. Tsagarakis S, Vassiliadi D, Thalassinos N 2006 Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest 29:471–482 23.
19. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH, 3rd, Nwariaku FE 2007 “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142:900–905.
20. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH, 3rd, Nwariaku FE 2007 “Subclinical Cushing’s syndrome” is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 142:900–905.
21. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing’s syndrome in patients with adrenal incidentaloma. Eur J Endocrinol 2002;146: 61-6.
22. Reincke M Subclinical Cushing’s syndrome. Endocrinol Metab Clin North Am 2000 – 29:43–56.
23. Pacak K Preoperative management of the pheochromocytoma patient. 2007 J Clin Endocrinol 2278 Metab 92:4069-4079.
24. Williams DT, Dann S, Wheeler MH Phaeochromocytoma--views on current management. 2003 Eur J Surg Oncol 29:483-90.
25. Kinney MA et al. Perioperative management of pheochromocytoma. 2002J Cardiothorac Vasc Anesth 16: 359–369
26. Pacak K et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. 2001Ann Intern Med 134: 315–329
27. Дедов ИИ, Бельцевич ДГ, Кузнецов НС, Мельниченко ГА. Феохромоцитома. Москва, РФ: Практ. медицина; 2005. с. 47–70.
28. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, September 2008, 93 (9):3266-3281.
29. Трошина Е.А., Бельцевич Д.Г., Молашенко Н.В. Диагностика и дифференциальная диагностика первичного гиперальдостеронизма. Клиническая медицина 2009;5:15–20.
30. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. 2000 - Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. Feb;85(2):637-44.
31. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997;47:279-83.
32. U. Metser E. Miller, H Lerman, G Lievshitz, S Avital, E Even-Sapir. - 18F-FDG PET/CT in the Evaluation of Adrenal Masses. –J Nucl Med - 2006-vol. 47 № 1. Р. 32-37.
33. M. Blake, P. Prakash, C.Cronin. PET/CT for Adrenal Assessment - Am J Roentgenology, 2010, V 195, N 2, 195.
34. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91:2665.
35. Leboulleux S, Dromain C, Bonniaud G, et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2006; 91:920.
36. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer 2011; 2:354.
37. Harisinghani MG, Maher MM, Hahn PF, et al. Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clin Radiol 2002;57:898-901.
38. Arellano RS, Harisinghani MG, Gervais DA, Hahn PF, Mueller PR. Imageguided percutaneous biopsy of the adrenal gland: review of indications, technique, and complications. Curr Probl Diagn Radiol 2003;32:3-10.
39. Welch TJ, Sheedy PF II, Stephens DH, Johnson CM, Swensen SJ. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology 1994;193:341-4.
40. Casola G, Nicolet V, van Sonnenberg E, et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology 1986;159:733-5.
41. McCorkell SJ, Niles NL. Fine-needle aspiration of catecholamine-producing adrenal masses: a possibly fatal mistake. AJR Am J Roentgenol 1985;145:113-4.
42. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez- Roqueplo AP, Grossman AB, Kimura N, Mannelli M, McNicol AM, Tischler AS 2007 pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 3:92–102.
43. W. Saeger, M. Fassnacht, R. Chita. - High Diagnostic Accuracy of Adrenal CoreBiopsy: Results of the German and Austrian Adrenal Network Multicenter Trial in 220 Consecutive Patients. Human pathology – 2003, v. 34, No. 2 – p.180-186.
44. Dackiw AP, Lee JE, Gagel RF, Evans DB - Adrenal cortical carcinoma. – 2001 - World J Surg 25:914-926
45. Ng L, Libertino JM - Adrenocortical carcinoma: diagnosis, evaluation and treatment. – 2003 - J Urol 169:5-11
46. Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg 2010; 395:955.
47. Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009; 115:243.
|
|
|
48. Wängberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer 2010; 17:265.
49. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 2006; 91:2027.
50. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., АнтоновА.К., Смелкова Н.И.. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. //Вестник новых медицинских технологий (электронное издание).–2013-№1-[Электронный ресурс].
51. Reibetanz J, Jurowich C, Erdogan I, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg 2012; 255:363.
52. Gaujoux S; Brennan MF Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery; 2012 Jul; 152(1):123-32.
53. Porpiglia F, Miller BS, Manfredi M, et al. A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma. Horm Cancer 2011; 2:372.
54. Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 2010; 58:609.
55. McCauley LR, Nguyen MM. Laparoscopic radical adrenalectomy for cancer: long-term outcomes. Curr Opin Urol 2008; 18:134.
56. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery. 2005;138(6):1078.
57. Weiss LM, Am J Surg Pathol. 1984 Mar; 8(3):163-9.
58. Lau SK, Weiss LM The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009 Jun;40(6):757-68.
59. van Slooten H., Schaberg A., Smeenk D., Moolenar A.J. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985 Feb 15;55(4):766-73.
60. Blanes A,et al. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007 Mar;127(3):398-408.
61. Филиппова О.В. Адренокортикальный рак: клинические проявления и морфологическая диагностика / Филиппова О.В., Хмельницкая Н.М. // Медицинский альманах. – 2011. – №5. – С. 113 – 116.
62. Hahner S, Fassnacht M 2005 Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6:386–394
63. Schteingart DE 2000 Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res 33:1197–1200
64. Lubitz JA, Freeman L, Okun R 1973 Mitotane use in inoperable adrenalcortical carcinoma. JAMA 223:1109–1112.
65. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D 1984 The treatment of adrenocortical carcinoma with o,p_-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20:47–5.
66. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM 1994 Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69:947–951.
|
|
|
67. Baudin E, Pellegriti G, Bonnay M, Penfornis A, lanche A, Vassal G,Schlumberger M 2001 Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92:1385–1392.
68. Heilmann P, Wagner P, Nawroth PP, Ziegler R 2001 [Therapy of the adrenocortical carcinoma with Lysodren (o,p’-DDD). Therapeutic management by monitoring o,p_-DDD blood levels]. Med Klin 96:371–377;
69. Becker D, Schumacher OP 1975.- o,p’DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med 82:677–679.
70. Boven E, Vermorken JB, van Slooten H, PinedoHM1984 Complete response of metastasized adrenal cortical carcinoma with o,p_-DDD. Case report and literature review. Cancer 53:26–29.
71. Krzisnik C, Petric G, Jereb B 1988 Complete response of metastatic adrenal cortical carcinoma to o,p_-DDD in a child. Pediatr Hematol Oncol 5:65–69.
72. Lim MC, Tan YO, Chong PY, Cheah JS 1990 Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore.
73. Decker RA, Kuehner ME 1991 Adrenocortical carcinoma. Am Surg 57:502– 513.
74. Remond S, Bardet S, Charbonnel B 1992 [Complete and lasting remission of a metastatic malignant adrenocortical carcinoma under treatment with OP- _DDD alone]. Presse Med 21:865.
75. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A 2001 Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest 24:532–535.
76. Allolio B, Hahner S, Weismann D, Fassnacht M 2004 Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60:273–287 19:540–544.;
77. Hague RV, May W, Cullen DR 1989 Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 31:51–57.
78. Dickstein G 1999 Is there a role of low dose of mitotane as adjuvant therapy in adrenocortical carcinoma? J Clin Endocrinol Metab 84:1488–1489.
79. Vassilopoulou-Sellin R, Guinee VF, Klein MJ, Taylor SH, Hess KR, Schultz PN, Samaan NA 1993 Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71:3119–3123
80. Terzolo M, Angeli A, Fassnacht M Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372.
81. Clinical trials gov. identifier NCT00777244, start 2008, update 2013.
82. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011; 7:323.
83. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. - 1990 - J Histochem Cytochem 38:1277-1287.
84. Flynn SD, Murren JR, Kirby WM, Honig J, Kan L, Kinder BK P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. - 1992 - Surgery 112:981-986.
85. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I Expression of a multidrug resistance gene in human cancers. - 1989 - J Natl Cancer Inst 81:116-124.
86. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. – 1994 - An-ticancer Res 14:1009-1016.
87. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. - 1993 - Eur J Cancer 29A:1036-1038.
88. Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study GroupN Engl J Med. 2012;366(23):2189.
89. Icard P, Goudet P, Charpenay C, 2001 Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg 25:891–897.
90. Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P 1996 The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119:161–170.
91. Pommier RF, Brennan MF 1992 An eleven-year experience with adrenocortical carcinoma. Surgery 112:963–970; discussion, 970–971.
92. Soreide JA, Brabrand K, Thoresen SO 1992 Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg 16:663– 667; discussion, 668.
93. Vassilopoulou-Sellin R, Schultz PN 2001 Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer 92:1113–1121.
